Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Guggenheim Healthcare Innovation Conference on Wednesday, November 13, 2024 at 3:30 p.m. Eastern time.

A live audio webcast of the fireside chat presentation will be available at https://wsw.com/webcast/guggen/kros/1967811 and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.

About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. Keros’ second product candidate, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.

Investor Contact:
Justin Frantz
jfrantz@kerostx.com    
617-221-6042    

Staff

Recent Posts

Aulisa® Medical Expands Access with New Leasing Options for Procuring Advanced Monitoring Solutions

PALO ALTO, Calif., Nov. 7, 2024 /PRNewswire/ -- Aulisa® Medical USA, Inc., a leader in…

5 hours ago

Shanghai thriving as global investment hub

BEIJING, Nov. 7, 2024 /PRNewswire/ -- A news report from chinadaily.com.cn: The 2024 Shanghai City Investment…

5 hours ago

Medexus Announces Strong Fiscal Q2 2025 Results

Fiscal Q2 2025 revenue of $26.3 million, net income of $0.1 million, operating income of…

11 hours ago

Front Porch announces Brain and Balance Center in Carlsbad, California

Carlsbad By The Sea senior living community develops innovative, empowering program CARLSBAD, Calif., Nov. 7,…

11 hours ago

NUTEX HEALTH REPORTS THIRD QUARTER AND YEAR TO DATE SEPTEMBER 30, 2024 FINANCIAL RESULTS

TOTAL REVENUE OF $222.3 MILLION FOR THE FIRST NINE MONTHS OF 2024 VS. $178.0 MILLION…

11 hours ago

Solventum Reports Third Quarter 2024 Financial Results and Raises Full-Year Guidance

Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3%GAAP Earnings Per Share (EPS)…

11 hours ago